1. Home
  2. GXAI vs IMRN Comparison

GXAI vs IMRN Comparison

Compare GXAI & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gaxos.ai Inc.

GXAI

Gaxos.ai Inc.

HOLD

Current Price

$0.58

Market Cap

8.6M

Sector

N/A

ML Signal

HOLD

Logo Immuron Limited

IMRN

Immuron Limited

HOLD

Current Price

$1.24

Market Cap

9.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GXAI
IMRN
Founded
2021
1994
Country
United States
Australia
Employees
3
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.6M
9.6M
IPO Year
2022
2016

Fundamental Metrics

Financial Performance
Metric
GXAI
IMRN
Price
$0.58
$1.24
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
227.7K
3.5M
Earning Date
05-14-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
71.35
N/A
EPS
N/A
N/A
Revenue
$1,933,030.00
N/A
Revenue This Year
$271.23
N/A
Revenue Next Year
$36.32
N/A
P/E Ratio
N/A
N/A
Revenue Growth
47901.74
N/A
52 Week Low
$0.59
$0.68
52 Week High
$2.63
$2.38

Technical Indicators

Market Signals
Indicator
GXAI
IMRN
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
GXAI
IMRN

About GXAI Gaxos.ai Inc.

Gaxos.AI Inc is a technology company focused on reshaping the way people interact with artificial intelligence across everyday life and high-impact industries. It is engaged in building a portfolio of AI-powered solutions designed to make advanced technology more practical, accessible, and transformative. The company's portfolio spans defense, health and wellness, entertainment, and productivity - bringing intelligent tools to markets where innovation can drive meaningful real-world outcomes. It operates as a single operating segment technology-based company that is developing applications aimed at redefining the way it utilizes artificial intelligence (AI) to optimize the user experience.

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

Share on Social Networks: